Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration …

– Collaboration Will Leverage Lantern's RADR® A.I. Platform to Accelerate Development of Actuate's Drug Candidate, 9-ING-41
– Actuate's 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases
– Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development
DALLAS, May 3, 2021 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its […]
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration …